Schonfeld Strategic Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-114,520	Closed	-$11.7M	–	2488
2023 Q2	$11.7M	Buy	114,520 +59,557	+108%	+$5.64M	0.1%	311
2023 Q1	$5M	Sell	54,963 -207,641	-79%	-$12.2M	0.05%	446
2022 Q4	$9.98M	Sell	262,604 -30,896	-11%	-$1.06M	0.08%	305
2022 Q3	$7.38M	Buy	+293,500	New	+$8.13M	0.06%	405
2022 Q2	–	Sell	-46,300	Closed	-$1.52M	–	3186
2022 Q1	$1.52M	Buy	+46,300	New	+$1.37M	0.01%	834
2020 Q3	–	Sell	-8,650	Closed	-$1.35M	–	1750
2020 Q2	$1.35M	Buy	8,650 +1,375	+19%	+$209K	0.03%	522
2020 Q1	$1.05M	Sell	7,275 -10,301	-59%	-$1.99M	0.07%	353
2019 Q4	$3.59M	Buy	17,576 +12,776	+266%	+$2.33M	0.09%	252
2019 Q3	$385K	Sell	4,800 -3,600	-43%	-$306K	0.01%	719
2019 Q2	$792K	Buy	+8,400	New	+$725K	0.03%	508
2018 Q1	–	Sell	-35,000	Closed	-$991K	–	1021
2017 Q4	$991K	Buy	35,000 +10,000	+40%	+$279K	0.08%	311
2017 Q3	$778K	Buy	+25,000	New	+$752K	0.07%	309

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's RETA Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 114,520 shares — an estimated $11.7M sold.

Schonfeld Strategic Advisors first reported a position in RETA in Q3 2017 and held it in 12 quarters. The position peaked at $11.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Schonfeld Strategic Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 114,520 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $11.7M.
Schonfeld Strategic Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 12 quarters.
Schonfeld Strategic Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11.7M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.